Shares Bazaar

Sun Pharmaceutical Industries Ltd.   (BSE: SUNPHARMA)

NSE   0.00  
OPEN PRICE(₹)
0.00
HIGH PRICE(₹)
0.00
LOW PRICE(₹)
0.00
CLOSE PRICE(₹)
0.00
VOLUME
0.00
52 WK LOW (₹)
452.25 (29-10-2020)
52 WK HIGH (₹)
721.85 (11-05-2021)
BSE   809.05  
OPEN PRICE₹)
819.5
HIGH PRICE(₹)
819.6
LOW PRICE (₹)
801.3
CLOSE PRICE(₹)
809.05
VOLUME
261897
VALUE
211888000
BID QTY
0
OFFER QTY
0

Stock Summary

Trade Value (₹ in Lacs) : 2147.48 MCap (₹ in Mn) : 1354184.66 Dividend Yield(%) : 0.71 Price/Earning (TTM) : 47
TTM EPS (₹) : 0 Price/Sales (TTM) : 0 P/E Ratio : 0 Price/Book (MRQ) : 5.32
Book Value(₹) : 0 Face Value(₹) : 0 Latest Reserve (₹ in Mn): 252166.2 EPSc : 13.38
PE : 42.17 TTMNP : 28813.7 TTMTAX : -27.4 TTMINTEREST : 3186.1
TTMDEPRECIATION : 5750 TTMNetSales : 117571.2 EV_Sales : 12.01 EV (in Mn) : 1411695.66
TTMEBITDA : 37722.4 EV_EBITDA : 37.42 TTMCashProfit : 34563.7 TTMCEPS : 14.41
Price_CEPS : 39.18 TTMNPAEX : 28813.7

Peer Group Compare

Comp. Name Price M.Cap Div Yld % P/E Ratio Price/Earning (TTM) TTM EPS (₹)
Divis Laboratories Ltd. (BSE)

4178.85 ( -3.53%)

91003.96 0.47 0.06 51.76 66.23
Dr. Reddys Laboratories Ltd. (BSE)

4498.5 ( -2.06%)

81092.78 0.51 0.04 33.02 147.67
Cipla Ltd. (BSE)

866.9 ( -1.79%)

67867.68 0.48 0.01 30.26 27.81
Aurobindo Pharma Ltd. (BSE)

655.2 ( -0.97%)

55333.11 0.32 0.01 20.8 45.4
Lupin Ltd. (BSE)

903.45 ( -3.81%)

47639.05 0.57 0.01 54.89 19.13

Management Info

Chairman : Israel Makov
Managing Director : Dilip S Shanghvi
Company Secretory : Sunil R Ajmera
Incorporation Year : 1993

Registered Office

Address : Sun Pharma Advanced Research Centre (S P A R C)
Tandalja

City-Pincode : Vadodara-390020
Phone : 0265- 5515500 / 5515600 / 5515700
Website : www.sunpharma.com
Email : secretarial@sunpharma.com

Registrars Details

Registrars Details : Link Intime India Pvt Ltd.
Address : C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai(Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra
Listing : BSE, NSE, MCX

Balance Sheet

(₹ in Million)
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
SOURCES OF FUNDS:
Share Capital 2.4 2.4 2.4 2.4 2.41
  Equity - Authorised 5.99 5.99 5.99 5.99 5.99
  Equity - Issued 2.4 2.4 2.4 2.4 2.41
 Equity Paid Up 2.4 2.4 2.4 2.4 2.41
  Equity Shares Forfeited 0.00 0.00 0.00 0.00 0.00
  Adjustments to Equity 0.00 0.00 0.00 0.00 0.00
  Preference Capital Paid Up 0.00 0 0 0 0
  Face Value 0 0 0 0 0
Share Warrants & Outstandings 0.00 0.00 0.00 0.00 0.00
Total Reserves 450.25 411.69 380.74 363.97 327.36
  Securities Premium 11.87 11.93 11.93 11.89 18.59
  Capital Reserves 3.68 3.68 0.51 0.51 0.46
  Profit & Loss Account Balances 353.2 333.3 319.78 306.46 251.63
  General Reserves 35.62 35.62 35.58 35.58 35.58
Reserve excluding Revaluation Reserve 450.25 411.69 380.74 363.97 327.36
Revaluation Reserves 0.00 0 0 0 0
Deposits 0.00 0.00 0.00 0.00 0.00
  Demand Deposits 0.00 0.00 0.00 0.00 0.00
  Savings Deposit 0.00 0.00 0.00 0.00 0.00
  Term Deposits / Fixed Deposits 0.00 0.00 0.00 0.00 0.00
  Current Deposits 0.00 0.00 0.00 0.00 0.00
  Recurring Deposits 0.00 0.00 0.00 0.00 0.00
  Other Deposits 0.00 0.00 0.00 0.00 0.00
Borrowings 0.00 0.00 0.00 0.00 0.00
  Borrowings From Reserve Bank of India 0.00 0.00 0.00 0.00 0.00
  Borrowings From Other Banks 0.00 0.00 0.00 0.00 0.00
  Borrowings From GOI 0.00 0.00 0.00 0.00 0.00
  Borrowings From Other Financial Institutions 0.00 0.00 0.00 0.00 0.00
  Borrowings in the form of Bonds / Debentures 0.00 0.00 0.00 0.00 0.00
  Borrowings in Other Form 0.00 0.00 0.00 0.00 0.00
Other Liabilities & Provisions 0.00 0.00 0.00 0.00 0.00
  Bills Payable 0.00 0.00 0.00 0.00 0.00
  Inter-office adjustment Liabilities 0.00 0.00 0.00 0.00 0.00
  Interest Accrued 0.00 0.00 0.00 0.00 0.00
  Proposed Dividend 0.00 0.00 0.00 0.00 0.00
  Corporate dividend tax payable 0.00 0.00 0.00 0.00 0.00
  Other Liabilities & Provisions 5.11 4.3 4.04 12.11 18.96
Total Liabilities 524.88 472.5 444.33 432.08 422.84
APPLICATION OF FUNDS :
Cash and balance with Reserve Bank of India 0.00 0.00 0.00 0.00 0.00
  Cash with RBI 0.00 0.00 0.00 0.00 0.00
  Cash in hand & others 0.00 0.00 0.00 0.00 0.00
Balances with banks and money at call 0.00 0.00 0.00 0.00 0.00
Investments 142.53 117.73 132.46 57.18 51.06
Investments in India 0.00 0.00 0.00 0.00 0.00
  GOI/State Govt. Securities 0.00 0.00 0.00 0.00 0.00
  Equity Shares - Corporate 0.00 0.00 0.00 0.00 0.00
  Debentures & Bonds 0.00 0.00 0.00 0.00 0.00
  Subsidiaries and/or joint ventures/Associates 0.00 0.00 0.00 0.00 0.00
  Units - MF/ Insurance/CP/PTC 0.00 0.00 0.00 0.00 0.00
Investments outside India 0.00 0.00 0.00 0.00 0.00
  Government securitiesC 0.00 0.00 0.00 0.00 0.00
  Subsidiaries and/or joint ventures abroad 0.00 0.00 0.00 0.00 0.00
  Other investments outside India 0.00 0.00 0.00 0.00 0.00
  Less: Prov for Diminution in Value of Invest. 0.00 0.00 0.00 0.00 0.00
Advances 0.00 0.00 0.00 0.00 0.00
  Bills Purchased & Discounted 0.00 0.00 0.00 0.00 0.00
  Cash Credit, Over Draft & Loans repayable 0.00 0.00 0.00 0.00 0.00
  Term Loans 0.00 0.00 0.00 0.00 0.00
  Finance lease and hire purchase receivable 0.00 0.00 0.00 0.00 0.00
Gross block 351.16 316.87 269.49 244.66 221.8
  Premises 58.44 54.14 48.77 47.17 44.12
  Assets Given on Lease 0.00 0.00 0.00 0.00 0.00
  Other Fixed Assets 0.00 0.00 0.00 0.00 0.00
Less: Accumulated Depreciation 122.69 98.51 80.96 67.91 63.08
Net Block 228.47 218.37 188.53 176.75 158.72
Less: Impairment of Assets 0.00 0.00 0.00 0.00 0.00
Lease Adjustment 0.00 0.00 0.00 0.00 0.00
Capital Work in Progress 12.2 14.11 24.65 28.01 21.75
Other Assets 0.00 0.00 0.00 0.00 0.00
  Inter-office adjustment Assets 0.00 0.00 0.00 0.00 0.00
  Interest Accrued Assets 0.00 0.00 0.00 0.00 0.00
  Tax paid in advance/TDS 0.00 0.00 0.00 0.00 0.00
  Stationery and stamps 0.00 0.00 0.00 0.00 0.00
  Non-banking assets acquired 0.00 0.00 0.00 0.00 0.00
  Deferred tax asset 0.00 0.00 0.00 0.00 0.00
  Miscellaneous Expenditure not written off 0.00 0.00 0.00 0.00 0.00
Total Assets 524.88 472.5 444.33 432.08 422.84
Contingent Liabilities 49.82 50.31 70.13 69.38 41.38
  Claims not acknowledged as debts 47.61 46.93 67.28 67.13 38.7
  Outstanding forward exchange contracts 0.00 0.00 0.00 0.00 0.00
  Guarantees given in India 0.00 0.00 0.00 0.00 0.00
  Guarantees given Outside India 0.00 0.00 0.00 0.00 0.00
  Acceptances, endorsements & other obligations 0.00 0.00 0.00 0.00 0.00
Bills for collection 0.00 0.00 0.00 0.00 0.00
Book Value 0.19 0.17 0.16 0.15 0.00
Adjusted Book Value 0.19 0.17 0.16 0.15 0.14
(₹ in Million)
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
SOURCES OF FUNDS:
Share Capital 2.4 2.4 2.4 2.4 2.41
  Equity - Authorised 5.99 5.99 5.99 5.99 5.99
  Equity - Issued 2.4 2.4 2.4 2.4 2.41
 Equity Paid Up 2.4 2.4 2.4 2.4 2.41
  Equity Shares Forfeited 0.00 0.00 0.00 0.00 0.00
  Adjustments to Equity 0.00 0.00 0.00 0.00 0.00
  Preference Capital Paid Up 0.00 0.00 0.00 0.00 0.00
  Face Value 0 0 0 0 0
Share Warrants & Outstandings 0.00 0.00 0.00 0.00 0.00
Total Reserves 241.56 226.04 220.83 207.7 216.44
  Securities Premium 11.87 11.93 11.93 11.89 18.59
  Capital Reserves 53.58 53.58 53.58 36.12 36.66
  Profit & Loss Account Balances 140.05 123.85 120.37 124.86 126.35
  General Reserves 34.78 34.78 34.78 34.78 34.78
Reserve excluding Revaluation Reserve 241.56 226.04 220.83 207.7 216.44
Revaluation Reserves 0.00 0.00 0.00 0.00 0.00
Deposits 0.00 0.00 0.00 0.00 0.00
  Demand Deposits 0.00 0.00 0.00 0.00 0.00
  Savings Deposit 0.00 0.00 0.00 0.00 0.00
  Term Deposits / Fixed Deposits 0.00 0.00 0.00 0.00 0.00
  Current Deposits 0.00 0.00 0.00 0.00 0.00
  Recurring Deposits 0.00 0.00 0.00 0.00 0.00
  Other Deposits 0.00 0.00 0.00 0.00 0.00
Borrowings 0.00 0.00 0.00 0.00 0.00
  Borrowings From Reserve Bank of India 0.00 0.00 0.00 0.00 0.00
  Borrowings From Other Banks 0.00 0.00 0.00 0.00 0.00
  Borrowings From GOI 0.00 0.00 0.00 0.00 0.00
  Borrowings From Other Financial Institutions 0.00 0.00 0.00 0.00 0.00
  Borrowings in the form of Bonds / Debentures 0.00 0.00 0.00 0.00 0.00
  Borrowings in Other Form 0.00 0.00 0.00 0.00 0.00
Other Liabilities & Provisions 0.00 0.00 0.00 0.00 0.00
  Bills Payable 0.00 0.00 0.00 0.00 0.00
  Inter-office adjustment Liabilities 0.00 0.00 0.00 0.00 0.00
  Interest Accrued 0.00 0.00 0.00 0.00 0.00
  Proposed Dividend 0.00 0.00 0.00 0.00 0.00
  Corporate dividend tax payable 0.00 0.00 0.00 0.00 0.00
  Other Liabilities & Provisions 28.69 12.47 14.35 22.22 29.15
Total Liabilities 286.83 255.32 253.23 239.96 267.29
APPLICATION OF FUNDS :
Cash and balance with Reserve Bank of India 0.00 0.00 0.00 0.00 0.00
  Cash with RBI 0.00 0.00 0.00 0.00 0.00
  Cash in hand & others 0.00 0.00 0.00 0.00 0.00
Balances with banks and money at call 0.00 0.00 0.00 0.00 0.00
Investments 213.76 215.09 219.67 227.22 250.19
Investments in India 0.00 0.00 0.00 0.00 0.00
  GOI/State Govt. Securities 0.00 0.00 0.00 0.00 0.00
  Equity Shares - Corporate 0.00 0.00 0.00 0.00 0.00
  Debentures & Bonds 0.00 0.00 0.00 0.00 0.00
  Subsidiaries and/or joint ventures/Associates 0.00 0.00 0.00 0.00 0.00
  Units - MF/ Insurance/CP/PTC 0.00 0.00 0.00 0.00 0.00
Investments outside India 0.00 0.00 0.00 0.00 0.00
  Government securitiesC 0.00 0.00 0.00 0.00 0.00
  Subsidiaries and/or joint ventures abroad 0.00 0.00 0.00 0.00 0.00
  Other investments outside India 0.00 0.00 0.00 0.00 0.00
  Less: Prov for Diminution in Value of Invest. 0.00 0.00 0.00 0.00 0.00
Advances 0.00 0.00 0.00 0.00 0.00
  Bills Purchased & Discounted 0.00 0.00 0.00 0.00 0.00
  Cash Credit, Over Draft & Loans repayable 0.00 0.00 0.00 0.00 0.00
  Term Loans 0.00 0.00 0.00 0.00 0.00
  Finance lease and hire purchase receivable 0.00 0.00 0.00 0.00 0.00
Gross block 82.45 74.61 65.73 49.88 41.04
  Premises 15.34 14.67 14.18 12.3 11.09
  Assets Given on Lease 0.00 0.00 0.00 0.00 0.00
  Other Fixed Assets 0.00 0.00 0.00 0.00 0.00
Less: Accumulated Depreciation 30.16 24.83 19.28 9.49 5.29
Net Block 52.29 49.78 46.45 40.39 35.75
Less: Impairment of Assets 0 0 0 0 0
Lease Adjustment 0.00 0.00 0.00 0.00 0.00
Capital Work in Progress 5.97 6.43 9.88 11.01 7.68
Other Assets 0.00 0.00 0.00 0.00 0.00
  Inter-office adjustment Assets 0.00 0.00 0.00 0.00 0.00
  Interest Accrued Assets 0.00 0.00 0.00 0.00 0.00
  Tax paid in advance/TDS 0.00 0.00 0.00 0.00 0.00
  Stationery and stamps 0.00 0.00 0.00 0.00 0.00
  Non-banking assets acquired 0.00 0.00 0.00 0.00 0.00
  Deferred tax asset 0.00 0.00 0.00 0.00 0.00
  Miscellaneous Expenditure not written off 0.00 0.00 0.00 0.00 0.00
Total Assets 286.83 255.32 253.23 239.96 267.29
Contingent Liabilities 33.86 39.02 56.03 54.06 25.85
  Claims not acknowledged as debts 32.19 36.24 53.59 52.09 24.61
  Outstanding forward exchange contracts 0.00 0.00 0.00 0.00 0.00
  Guarantees given in India 0.00 0.00 0.00 0.00 0.00
  Guarantees given Outside India 0.00 0.00 0.00 0.00 0.00
  Acceptances, endorsements & other obligations 0.00 0.00 0.00 0.00 0.00
Bills for collection 0.00 0.00 0.00 0.00 0.00
Book Value 0.1 0.1 0.09 0.09 0.09
Adjusted Book Value 0.1 0.1 0.09 0.09 0.09

Quarterly Results

Particulars Sep-2020 Jun-2020 Mar-2020 Feb-2019
Date End Audited Audited Audited Audited
Interest Earned 85531.30 75852.50 81849.40 81548.50
Income On Investments 0.00 0.00 0.00 0.00
Interest On Balances With Rbi Other Inter Bank Funds 0.00 0.00 0.00 0.00
Interest / Discount On Advances / Bills 0 0 0 0
Others 0 0 0 0
Other Income 2557.8 2329.5 1022.3 2016.8
Total Income 88089.1 78182 82871.7 83565.3
Interest Expended 332.8 519.5 517.8 629.6
Operating Expenses 0 0 0 0
Total Expenditure 63598.5 58209 68219.3 63952.5
Operating Profit Before Provisions and Contingencies 24490.6 19973 14652.4 19612.8
Exceptional Items 0 -36333.3 -2606.4 0
Provisions and contingencies 0 0 0 0
Profit Before Tax 19171.8 -21839 5774.4 13513.3
Tax -312 2459.1 830.9 3276.2
Profit After Tax 19483.8 -24298.1 4943.5 10237.1
+/- Extraordinary Items 0 0 0 0
+/- Prior period items 0 0 0 0
Net Profit 19483.8 -24298.1 4943.5 10237.1
Minority Interest -1299.7 7706.3 -929.2 -1058.6
Shares of Associates -56.2 35.8 -15.9 -43.3
Other related items 0 0 0 0
Misc. Expenses Written off 0.00 0.00 0.00 0.00
Consolidated Net Profit 19483.8 -24298.1 4943.5 10237.1
Equity Capital 18127.9 -16556 3998.4 9135.2
Face Value (IN RS) 1 1 1 1
Reserves 0 0 0 0
% of Shares held by Govt 0 0 0 0
Capital Adequacy Ratio 0.00 0.00 0.00 0.00
Gross / Net NPAs 0.00 0.00 0.00 0.00
Amount of Gross NPAs 0.00 0.00 0.00 0.00
Amount of Net NPAs 0 0 0 0
% of Gross / Net NPAs NA NA NA NA
% of Net NPAs 0 0 0 0
% of Gross NPAs 0 0 0 0
Return on Assets 0 0 0 0
No of Public Share Holdings NA NA NA NA
% of Public Share Holdings NA NA NA NA
Basic Eps After Extraordinary Items 7.56 -6.9 1.67 3.81
Basic Eps Before Extraordinary Items 7.56 -6.9 1.67 3.81
PBIDTM% 28.63 26.33 17.9 24.05
PBDTM% 28.24 -22.25 14.08 23.28
PBTM% 22.42 -28.79 7.05 16.57
PATM% 22.78 -32.03 6.04 12.55
Particulars Mar-2020
Date End Audited
Interest Earned 28360.8
Income On Investments 0
Interest On Balances With Rbi Other Inter Bank Funds 0
Interest / Discount On Advances / Bills 0
Others 0.00
Other Income 9999.9
Total Income 40547.3
Interest Expended 1375.3
Operating Expenses 0.00
Total Expenditure 26075.4
Operating Profit Before Provisions and Contingencies 14471.9
Exceptional Items 0
Provisions and contingencies 0.00
Profit Before Tax 11672.2
Tax 113.7
Profit After Tax 11558.5
+/- Extraordinary Items 0.00
+/- Prior period items 0.00
Net Profit 11558.5
Minority Interest 0.00
Shares of Associates 0.00
Other related items 0.00
Misc. Expenses Written off 0.00
Consolidated Net Profit 11558.5
Equity Capital 11558.5
Face Value (IN RS) 1
Reserves 0
% of Shares held by Govt 0.00
Capital Adequacy Ratio 0.00
Gross / Net NPAs 0.00
Amount of Gross NPAs 0.00
Amount of Net NPAs 0.00
% of Gross / Net NPAs NA
% of Net NPAs 0.00
% of Gross NPAs 0.00
Return on Assets 0.00
No of Public Share Holdings NA
% of Public Share Holdings NA
Basic Eps After Extraordinary Items 4.82
Basic Eps Before Extraordinary Items 4.82
PBIDTM% 51.03
PBDTM% 46.18
PBTM% 41.16
PATM% 40.76

Profit-Loss

-
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
I. INCOME
Interest Earned 0 0 0 0 0
     Interest / Discount on advances / Bills 0 0 0 0 0
     Interest on balances with RBI and other Inter-bank funds 0 0 0 0 0
     Income on investments 0 0 0 0 0
     Others 0 0 0 0 0
Other Income
     Commission,exchange and brokerage 0 0 0 0 0
     Profit / (loss)on sale of investments(net) 0.82 1.61 1.47 0.2 0
     Profit on sale of Fixed Assets 0.03 0.03 0.03 0.02 1.47
     Foreign Exchange Gains 0.16 0 0 4.07 0
     Income earned from subsidiaries/joint venture 0 0 0 0 0
     Rent / Lease Income
     Provisions Written Back 0.05 0.4 0.17 0.62 0.18
     Miscellaneous income -19547.7 -21188.8 -18241.6 -30906 -6582.5
Total Income 334.89 301.25 273.28 323.38 287.67
II. EXPENDITURE
Interest Expended 3.03 5.55 5.18 4 5.23
     Intereston Deposits 0 0 0 0 0
     Interest on RBI / inter-bank borrowings 0 0 0 0 0
     Other Interest 3.03 5.55 5.18 4 5.23
Operating Expenses 0 0 0 0 0
     Payments to and provisions for employees 63.62 59.67 53.67 49.02 47.72
     Rent,Taxes and lighting 5.07 4.42 4.36 4.26 3.99
     Depreciation on Banks property 20.53 17.53 15 12.65 10.38
     Depreciation on leased assets
     Auditor's fees and expenses 0.27 0.26 0.2 0.23 0.26
     Law charges 19.08 14.37 16.15 14.64 18.86
     Communication Expenses 0.96 0.84 0.8 0.73 0.77
     Repairs and Maintenance 0 0 0 4.1 0
     Insurance 1.97 1.49 1.31 1.07 1.25
     Other expenses -111.5 -98.59 -91.49 -86.7 -83.23
Provisions and Contingencies
     Provision for investments
     Provision for advances
     Others Provisions
Profit Before Tax 331.86 295.7 268.1 319.39 282.44
Taxes
     Current Income Tax 13.2 8.04 6.63 4.05 11.95
     Deferred Tax -4.97 -2.03 2.48 8.07 -2.82
     Other taxes 0 0 0 0 0
Profit After Tax 41.87 32.09 25.68 78.36 56.57
Extra items
Minority Interest -4.07 -5.42 -4.47 -8.82 -11.13
Share of Associate -0.15 -0.01 -0.25 0.1 0.01
Other Consolidated Items
Consolidated Net Profit 37.65 26.65 20.96 69.64 45.46
Adjustments to PAT
IV. APPROPRIATIONS
     Transfer to Statutory Reserve
     Appropriation to General Reserve
     Appropriation to Revenue Reserve
     Appropriation to Other Reserves 17.75 13.13 10.43 14.81 10.57
     Equity Dividend
     Corporate dividend tax
     Other appropriations 353.2 333.3 319.78 306.46 251.63
Equity Dividend % 400.00 275.00 200.00 350.00 100.00
Earnings Per Share 15.6918 11.1092 8.7346 29.0267 18.8885
Adjusted EPS 15.6918 11.1092 8.7346 29.0267 18.8885
-
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
I. INCOME
Interest Earned 0 0 0 0 0
     Interest / Discount on advances / Bills 0 0 0 0 0
     Interest on balances with RBI and other Inter-bank funds 0 0 0 0 0
     Income on investments 0 0 0 0 0
     Others 0 0 0 0 0
Other Income
     Commission,exchange and brokerage 0 0 0 0 0
     Profit / (loss)on sale of investments(net) 2.37 1.98 1.42 2.43 3.24
     Profit on sale of Fixed Assets 0 0 0 0 0.18
     Foreign Exchange Gains 0 0 0.52 1.75 0
     Income earned from subsidiaries/joint venture 0 0 0 0 0
     Rent / Lease Income
     Provisions Written Back 2.52 0.18 0.28 0.03 0.05
     Miscellaneous income -30218.4 -25723 -37548.3 -20691 -8901.8
Total Income 140.43 115.89 102.34 83.74 81.78
II. EXPENDITURE
Interest Expended 4.08 5.41 3.88 2.24 5.74
     Intereston Deposits 0 0 0 0 0
     Interest on RBI / inter-bank borrowings 0 0 0 0 0
     Other Interest 4.08 5.41 3.88 2.24 5.74
Operating Expenses 0 0 0 0 0
     Payments to and provisions for employees 17.03 15.71 16.25 15 14.77
     Rent,Taxes and lighting 2.24 1.38 1.69 1.31 1.26
     Depreciation on Banks property 5.62 5.53 4.87 4.22 4.64
     Depreciation on leased assets
     Auditor's fees and expenses 0.04 0.04 0.03 0.04 0.05
     Law charges 5.65 4.55 4.75 3.81 6.31
     Communication Expenses 0.31 0.28 0.28 0.26 0.32
     Repairs and Maintenance 0 0 0 0 0
     Insurance 0.72 0.54 0.51 0.42 0.45
     Other expenses -31.59 -28.02 -28.39 -25.07 -27.81
Provisions and Contingencies
     Provision for investments
     Provision for advances
     Others Provisions
Profit Before Tax 136.35 110.48 98.46 81.5 76.04
Taxes
     Current Income Tax 3.86 0.02 0.02 0.06 0.05
     Deferred Tax -3.45 -0.99 -0.27 0 0
     Other taxes 0 0 0 0 0
Profit After Tax 32.11 8.17 3.06 -0.23 -10.88
Extra items
Minority Interest
Share of Associate
Other Consolidated Items
Consolidated Net Profit 32.11 8.17 3.06 -0.23 -10.88
Adjustments to PAT
IV. APPROPRIATIONS
     Transfer to Statutory Reserve
     Appropriation to General Reserve
     Appropriation to Revenue Reserve
     Appropriation to Other Reserves 7.7 4.69 7.55 1.26 8.96
     Equity Dividend
     Corporate dividend tax 1.01
     Other appropriations 147.25 123.85 120.37 124.87 126.35
Equity Dividend % 400 275 200 350 100
Earnings Per Share 13.38 3.40 1.27 -0.10 -4.52
Adjusted EPS 13.38 3.40 1.27 -0.10 -4.52

Financial Ratios

Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2015
Operational & Financial Ratios
Earnings Per Share (Rs) 15.69 11.11 8.73 29.03 21.92
DPS(Rs) 4 2.75 2 3.5 3
Book NAV/Share(Rs) 188.66 172.59 159.69 152.7 123.49
Margin Ratios
Yield on Advances 0 0 0 0 0
Yield on Investments 0 0 0 0 0
Cost of Liabilities 0 0 0 0 0
NIM 0 0 0 0 0
Interest Spread 0 0 0 0 0
Performance Ratios
ROA(%) 6.58 5.17 4.24 0 14.6
ROE(%) 9.66 8.05 6.85 0 24.89
ROCE(%) 10.07 8.68 8.4 0 25.06
Efficiency Ratios
Cost Income Ratio 0 0 0 0 0
Core Cost Income Ratio 0 0 0 0 0
Operating Costs to Assets 0 0 0 0 0
Capital Adequacy
Basel I
Total CAR (Basel I) 0 0 0 0 0
Tier-1 (Basel I) 0 0 0 0 0
Tier-2 (Basel I) 0 0 0 0 0
Basel II
Total CAR (Basel II) 0 0 0 0 0
Tier-1 (Basel II) 0 0 0 0 0
Tier-2 (Basel II) 0 0 0 0 0
Basel III
Total CAR (Basel III) 0 0 0 0 0
Tier - 1 (Basel III) 0 0 0 0 0
Tier - 2 (Basel III) 0 0 0 0 0
Valuation Parameters
PER(x) 22.44 43.14 56.72 23.69 46.64
PCE(x) 13.54 23.17 29.22 18.13 31.68
Price/Book(x) 1.87 2.78 3.1 4.5 8.28
Yield(%) 1.14 0.57 0.4 0.51 0.29
EV/Net Sales(x) 2.63 4.07 4.52 5.1 7.66
EV/Core EBITDA(x) 11.32 16.12 18.51 14.91 24.92
EV/EBIT(x) 16.25 27.08 29.86 16.9 30.04
EV/CE(x) 1.33 1.9 1.92 2.71 4.46
M Cap / Sales 2.57 3.96 4.5 5.27 7.73
Growth Ratio
Core Operating Income Growth -45.48 7.28 29.46 -23.59 1210.23
Operating Profit Growth 3.99 13.75 -39.82 21.5 11.42
Net Profit Growth 30.46 24.98 -67.23 38.53 41.49
BVPS Growth 9.31 8.08 4.58 0 38.07
Advances Growth 0 0 0 0 0
EPS Growth(%) 41.25 27.19 -69.91 53.67 44.5
Liquidity Ratios
Loans/Deposits(x) 0 0 0 0 0
Total Debt/Equity(x) 0 0 0 0 0
Current Ratio(x) 0 0 0 0 0
Quick Ratio(x) 0 0 0 0 0
Interest Cover(x)
Total Debt/Mcap(x) 0 0 0 0 0
Net NPA in Rs. Million 0 0 0 0 0
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
Operational & Financial Ratios
Earnings Per Share (Rs) 13.38 3.4 1.27 -0.1 -4.52
DPS(Rs) 4 2.75 2 3.5 1
Book NAV/Share(Rs) 100 95.21 93.04 87.57 90.94
Margin Ratios
Yield on Advances 0 0 0 0 0
Yield on Investments 0 0 0 0 0
Cost of Liabilities 0 0 0 0 0
NIM 0 0 0 0 0
Interest Spread 0 0 0 0 0
Performance Ratios
ROA(%) 8.36 2.17 0.86 -0.07 -2.97
ROE(%) 13.6 3.62 1.41 -0.11 -4.88
ROCE(%) 12.19 4.31 2.38 0.75 -1.77
Efficiency Ratios
Cost Income Ratio 0 0 0 0 0
Core Cost Income Ratio 0 0 0 0 0
Operating Costs to Assets 0 0 0 0 0
Capital Adequacy
Basel I
Total CAR (Basel I) 0 0 0 0 0
Tier-1 (Basel I) 0 0 0 0 0
Tier-2 (Basel I) 0 0 0 0 0
Basel II
Total CAR (Basel II) 0 0 0 0 0
Tier-1 (Basel II) 0 0 0 0 0
Tier-2 (Basel II) 0 0 0 0 0
Basel III
Total CAR (Basel III) 0 0 0 0 0
Tier - 1 (Basel III) 0 0 0 0 0
Tier - 2 (Basel III) 0 0 0 0 0
Valuation Parameters
PER(x) 26.32 100 100 0 0
PCE(x) 22.4 83.96 100 100 -100
Price/Book(x) 3.46 5.03 5.32 7.85 9.01
Yield(%) 1.14 0.57 0.4 0.51 0.12
EV/Net Sales(x) 7.2 11.75 13.98 22.24 26.23
EV/Core EBITDA(x) 21.37 39.99 59.63 100 100
EV/EBIT(x) 24.65 96.07 100 100 -100
EV/CE(x) 2.33 3.18 3.38 4.99 5.86
M Cap / Sales 6.74 11.16 13.23 21.47 25.5
Growth Ratio
Core Operating Income Growth -24.57 39.3 73.69 -61.06 4.15
Operating Profit Growth 39.46 43.74 100 100 100
Net Profit Growth 100 100 100 97.9 26.23
BVPS Growth 6.8 2.33 6.25 -3.71 -17.13
Advances Growth 0 0 0 0 0
EPS Growth(%) 100 100 100 97.89 36.51
Liquidity Ratios
Loans/Deposits(x) 0 0 0 0 0
Total Debt/Equity(x) 0 0 0 0 0
Current Ratio(x) 0 0 0 0 0
Quick Ratio(x) 0 0 0 0 0
Interest Cover(x)
Total Debt/Mcap(x) 0 0 0 0 0
Net NPA in Rs. Million 0 0 0 0 0

Cash Flow

(₹ in Million)
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
Net Profit Before Taxes 50.1 38.1 34.79 90.48 65.71
Adjustments for Expenses & Provisions : 19.93 19.69 13.82 5.01 18.57
Adjustments for Liabilities & Assets: 8.99 -26.96 -2.12 -4.09 2.47
Refund/(payment) of direct taxes -13.46 -8.86 -7.42 -20.57 -19.88
Other Direct payments 0 0 0 0 0
Cash Flow from operating activities 65.55 21.96 39.07 70.82 66.86
Cash Flow from investing activities -25.89 -6.81 -33.71 -42.22 -43.72
Cash Flow from financing activities -57.15 -27.31 -15.39 -22.85 -18.89
Effect of exchange fluctuation on translation reserve 0 0 0 0 0
Net increase/(decrease) in cash and cash equivalents -17.49 -12.15 -10.03 5.75 4.26
Opening Cash & Cash Equivalents 70.62 79.06 86.42 80.32 71.83
Cash & Cash Equivalent on Amalgamation / Take over / Merger 0 0 0 0 0
Cash & Cash Equivalent of Subsidiaries under liquidations 0 0.46 1.2 0 0
Translation adjustment on reserves / op cash balalces frgn subsidiaries 0 0 0 0 0
Effect of Foreign Exchange Fluctuations 3.64 3.26 1.47 0.35 4.22
Closing Cash & Cash Equivalent 56.77 70.62 79.06 86.42 80.32
Cash & Cash Equivalent on Amalgamation / Take over / Merger 0 0 0 0 0
Cash & Cash Equivalent of Subsidiaries under liquidations 0 0.46 1.2 0 0
Translation adjustment on reserves / op cash balalces frgn subsidiaries 0 0 0 0 0
Effect of Foreign Exchange Fluctuations 3.64 3.26 1.47 0.35 4.22
(₹ in Million)
Particulars Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
Net Profit Before Taxes 50.1 38.1 34.79 90.48 65.71
Adjustments for Expenses & Provisions : 19.93 19.69 13.82 5.01 18.57
Adjustments for Liabilities & Assets: 8.99 -26.96 -2.12 -4.09 2.47
Refund/(payment) of direct taxes -13.46 -8.86 -7.42 -20.57 -19.88
Other Direct payments 0 0 0 0 0
Cash Flow from operating activities 65.55 21.96 39.07 70.82 66.86
Cash Flow from investing activities -25.89 -6.81 -33.71 -42.22 -43.72
Cash Flow from financing activities -57.15 -27.31 -15.39 -22.85 -18.89
Effect of exchange fluctuation on translation reserve 0 0 0 0 0
Net increase/(decrease) in cash and cash equivalents -17.49 -12.15 -10.03 5.75 4.26
Opening Cash & Cash Equivalents 70.62 79.06 86.42 80.32 71.83
Cash & Cash Equivalent on Amalgamation / Take over / Merger 0 0 0 0 0
Cash & Cash Equivalent of Subsidiaries under liquidations 0 0.46 1.2 0 0
Translation adjustment on reserves / op cash balalces frgn subsidiaries 0 0 0 0 0
Effect of Foreign Exchange Fluctuations 3.64 3.26 1.47 0.35 4.22
Closing Cash & Cash Equivalent 56.77 70.62 79.06 86.42 80.32
Cash & Cash Equivalent on Amalgamation / Take over / Merger 0 0 0 0 0
Cash & Cash Equivalent of Subsidiaries under liquidations 0 0.46 1.2 0 0
Translation adjustment on reserves / op cash balalces frgn subsidiaries 0 0 0 0 0
Effect of Foreign Exchange Fluctuations 3.64 3.26 1.47 0.35 4.22

Share Price

Year Open Price (₹) High Price (₹) Low Price (₹) Close Price (₹) Volume (000's) Value (in Lakhs)
February-2021 596 653.7 579.65 627.25 5222.3 32613.52
January-2021 593.45 627.95 550.7 586.45 7415.45 44119.95
December-2020 517 599.5 514.75 584.1 11676.45 66884.52
November-2020 469 526 459.3 511.55 6807.37 34437.71
October-2020 501.05 529.4 452.6 465.75 4842.75 23922.16
September-2020 520.15 535 483 500.5 6826.04 34913.79
August-2020 531.75 564.9 514.5 518.5 7238.76 38719.77
Sun Pharmaceutical recalling 696 bottles of Pregabalin capsules in US market17-Jan-2022 12:12 PM  
Sun Pharmaceutical Industries informs about loss of share certificates29-Dec-2021 04:33 PM  
Sun Pharma’s arm gets EUA to manufacture, market Molxvir in India28-Dec-2021 03:33 PM  
Sun Pharma's arm gets USFDA’s nod for generic Amphotericin B Liposome Injection16-Dec-2021 10:28 AM  
Sun Pharmaceutical Industries informs about disclosure15-Dec-2021 04:34 PM  
Sun Pharma’s arm settles case with Biofrontera 01-Dec-2021 11:05 AM  
Sun Pharmaceutical Industries informs about loss of share certificates24-Nov-2021 04:34 PM  
Sun Pharmaceutical falls on recalling over 1.10 lakh bottles of generic medication in US market22-Nov-2021 11:40 AM  
Sun Pharmaceutical recalling over 1.10 lakh bottles of generic medication in US market 22-Nov-2021 10:34 AM  
Sun Pharmaceutical Industries informs about loss of share certificate17-Nov-2021 02:59 PM  
Sun Pharma gearing up to introduce molnupiravir in India12-Nov-2021 09:30 AM  
Sun Pharma recalling 22,752 blister packs of Loratadine-D extended-release tablets08-Nov-2021 10:59 AM  
Sun Pharmaceutical Industries rises on reporting 13% rise in Q2 consolidated net profit02-Nov-2021 03:21 PM  
Sun Pharmaceutical Industries reports 13% rise in Q2 consolidated net profit 02-Nov-2021 03:12 PM  
Sun Pharma moves up on launching Winlevi cream in US market01-Nov-2021 02:31 PM  
Sun Pharmaceutical launches Winlevi cream in US market01-Nov-2021 12:16 PM  
Sun Pharma launches ILUMYA medicine to treat Plaque psoriasis in Canada 29-Oct-2021 12:30 PM  
Sun Pharmaceutical Industries informs about loss of share certificates27-Oct-2021 04:17 PM  
Sun Pharmaceutical Industries informs about certificate 14-Oct-2021 03:07 PM  
Sun Pharmaceutical Industries informs about press release28-Sep-2021 12:33 PM  
Sun Pharmaceutical Industries launches novel formulation in cough management ‘Chericof 12’28-Sep-2021 11:16 AM  
Sun Pharmaceutical Industries informs about loss of share certificates27-Sep-2021 03:22 PM  
Sun Pharma surges on foraying into nutrition bar segment08-Sep-2021 01:48 PM  
Sun Pharma forays into nutrition bar segment 08-Sep-2021 01:31 PM  
Sun Pharmaceutical rises on selling step-down subsidiary02-Sep-2021 12:03 PM  
Sun Pharmaceutical sells Kayaku Co02-Sep-2021 11:19 AM  
Sun Pharma gets exclusive right to commercialize Winlevi in US, Canada01-Sep-2021 10:15 AM  
Sun Pharmaceutical Industries informs about press release31-Aug-2021 01:03 PM  
Sun Pharmaceutical Industries informs about loss of share certificate19-Aug-2021 09:49 AM  
Sun Pharmaceutical Industries informs about schedule of analyst meet10-Aug-2021 04:38 PM  
Sun Pharmaceutical Industries turns black in Q1 30-Jul-2021 03:37 PM  
Sun Pharmaceutical, Cassiopea SpA sign license, supply agreements for Winlevi26-Jul-2021 11:14 AM  
Sun Pharmaceutical surges on launching special initiative ‘Sunkalp’ for welfare of doctors01-Jul-2021 11:23 AM  
Sun Pharmaceutical launches special initiative ‘Sunkalp’ for welfare of doctors01-Jul-2021 11:08 AM  
Sun Pharmaceutical Industries informs about press release22-Jun-2021 10:14 AM  
Sun Pharma enters patent litigation settlement with Celgene for launch of generic Revlimid 22-Jun-2021 10:10 AM  
Sun Pharmaceutical Industries informs about loss of share certificates19-Jun-2021 11:20 AM  
Sun Pharma trades in green on the BSE18-Jun-2021 02:14 PM  
Sun Pharmaceutical Industries eyeing biosimilars to fuel its future growth14-Jun-2021 02:45 PM  
Sun Pharmaceutical Industries informs about press release02-Jun-2021 04:34 PM  
Sun Pharma shines as its arm enters into license agreement with Ferring Pharmaceuticals02-Jun-2021 02:33 PM  
Sun Pharma’s arm enters into license agreement with Ferring Pharmaceuticals 02-Jun-2021 02:25 PM  
Sun Pharma rises on acquiring rights to trademarks of 3 diabetes drug brands in India01-Jun-2021 02:37 PM  
Sun Pharm acquires rights to trademarks of 3 diabetes drug brands in India from AstraZeneca28-May-2021 04:06 PM  
Sun Pharmaceutical Industries informs about disclosure27-May-2021 09:50 AM  
Sun Pharmaceutical Industries informs about change in directorate21-May-2021 10:34 AM  
Sun Pharmaceutical Industries informs about press release10-May-2021 04:45 PM  
Sun Pharma zooms on signing voluntary licensing agreement with Eli Lilly10-May-2021 02:15 PM  
Sun Pharma signs voluntary licensing agreement with Eli Lilly 10-May-2021 01:32 PM  
Sun Pharma trades in green on the BSE27-Apr-2021 02:30 PM  
Sun Pharma recalls 13,834 bottles of diabetes drug ‘Riomet’ in US market26-Apr-2021 09:00 AM  
Sun Pharma recalls products in US market19-Apr-2021 12:14 PM  
Sun Pharmaceutical Industries informs about loss of share certificate22-Mar-2021 01:18 PM  
Sun Pharma slips on recalling products in US market16-Mar-2021 12:54 PM  
Sun Pharmaceutical Industries recalls products in US market16-Mar-2021 11:58 AM  
Sun Pharma’s arm acquires stake in WRS Bioproducts Pty10-Mar-2021 03:43 PM  
Sun Pharma gains as its arm to acquire stake in WRS Bioproducts Pty08-Mar-2021 01:46 PM  
Sun Pharma’s arm agrees to acquire stake in WRS Bioproducts Pty06-Mar-2021 10:27 AM  
Sun Pharmaceutical Industries informs about disclosure05-Mar-2021 04:14 PM  
Sun Pharma jumps after launching website for long-term care division in US25-Feb-2021 11:33 AM  
Sun Pharmaceutical Industries informs about press release25-Feb-2021 10:12 AM  
Sun Pharma launches website for long-term care division in US25-Feb-2021 09:58 AM  
Sun Pharma to introduce complete range of Brivaracetam 23-Feb-2021 03:23 PM  
Sun Pharmaceutical Industries informs about press release23-Feb-2021 03:17 PM  
Sun Pharmaceutical Industries informs about record date for redemption of CP18-Feb-2021 11:11 AM  
Sun Pharmaceutical Industries informs about disclosure18-Feb-2021 09:31 AM  
Sun Pharma slips on recalling 36,275 cartons of testosterone injection in US for labelling error09-Feb-2021 02:16 PM  
Sun Pharma recalls 36,275 cartons of testosterone injection in US for labelling error 08-Feb-2021 09:30 AM  
Sun Pharma gains on reporting 2- fold jump in Q3 consolidated net profit02-Feb-2021 10:39 AM  
Sun Pharma reports 2- fold jump in Q3 consolidated net profit01-Feb-2021 04:24 PM  
Sun Pharmaceutical Industries informs about declaration of interim dividend21-Jan-2021 10:19 AM  
Sun Pharmaceutical Industries board to approve unaudited financial results04-Jan-2021 01:16 PM